Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Jensen, Alexandra D ^a   Krauss, Jürgen ^b   Potthoff, Karin ^a   Desta, Almaz ^c   Habl, Gregor ^a   Mavtratzas, Athanasios ^b   Windemuth Kiesselbach, Christine ^c   Debus, Jürgen ^a   Münter, Marc W ^a  

^a INF 400 ^*  (Germany)

^b National Centre for Tumour Disease (NCT)   (Germany)

^c ALCEDIS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; CARBON; ION; MONOCLONAL ANTIBODY; TAXOID;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LARYNX CARCINOMA; LOADING DRUG DOSE; OPEN STUDY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; CLINICAL TRIAL; GENETIC SCREENING; HYPOPHARYNX TUMOR; LARYNX TUMOR; MULTIMODALITY CANCER THERAPY; OROPHARYNX TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBON; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; GENETIC TESTING; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IONS; LARYNGEAL NEOPLASMS; OROPHARYNGEAL NEOPLASMS; RADIOIMMUNOTHERAPY; TAXOIDS;

EID: 79955996385     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-182     Document Type: Article

References (36)

1. NCCN guidelines for physicians as accessed on 12.12.2010 on. , http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955.
3. Pignon JP, le Maitre A, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007, 69:S112-114.
4. Pignon JP, le Maitre A, Maillard E, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. 10.1016/j.radonc.2009.04.014, 19446902.
5. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected lically advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006, 6:28. 10.1186/1471-2407-6-28, 1379652, 16448551.
6. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-854. 10.1016/S0140-6736(06)69121-6, 16950362.
7. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16. 10.1016/S0360-3016(00)00663-5, 10924966.
8. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086. 10.1093/jnci/91.24.2081, 10601378.
9. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98. 10.1200/JCO.2003.01.008, 12506176.
10. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
11. Münter MW, Karger CP, Hoefner SG, Hof H, Thilmann C, Rudat V, Nill S, Wannenmacher M, Debus J. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 2004, 58:175-184. 10.1016/S0360-3016(03)01437-8, 14697436.
12. Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001, 61:275-280. 10.1016/S0167-8140(01)00449-2, 11730997.
13. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991. 10.1016/j.ijrobp.2006.06.013, 17145528.
14. Nutting C, A'Hern R, Rogers MS, Sydenham MA, Adab F, Harrington K, Jefferies S, Scrase C, Yap BK, Hall E. On behalf of the PARSPORT Trial Management Group. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Proc ASCO 2009, abstr.# LBA6006.
15. Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, Jakel O, Karger CP, Debus J. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005, 104(2):338-44. 10.1002/cncr.21158, 15937907.
16. Münter M, Umathum V, Jensen AD, Hof H, Jaekel O, Debus J. Combination of intensity-modulated radiation therapy (IMRT) and a heavy ion (C12) boost for subtotal resected or inoperable adenoid cystic carcinomas (ACCs) of the head and neck region. J Clin Oncol 2010, 28:e16010.
17. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jakel O, Edler L, Scholz M, Debus J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007, 68:449-57. 10.1016/j.ijrobp.2006.12.059, 17363188.
18. Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jäkel O, Karger CP, Edler L, Debus J. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 2007, 67:171-177. 10.1016/j.ijrobp.2006.08.027, 17056193.
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
20. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28. 10.1016/S1470-2045(09)70311-0, 19897418.
21. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
22. Caudell JJ, Sawrie SM, Spencer SA, Desmoid RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetucimab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008, 71:676-681. 10.1016/j.ijrobp.2007.10.040, 18355979.
23. Fan Z, Baselga J, Masui H, Medelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-deamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53:4637-4642.
24. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708.
25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:1935-1940.
26. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-15. 10.1056/NEJMoa070956, 17960013.
27. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-704. 10.1056/NEJMoa071028, 17960012.
28. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005, 23:8636-8645. 10.1200/JCO.2004.00.1990, 16275937.
29. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A, Sastre J, Martinez J, Cortes-Funes H, Cruz-Hernandez J. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). Proc ASCO 2009, abstr.# 6009.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RA, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958, 53:457-481.
32. Gregoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology ans procedure based on surgical experience. Radiother Oncol 2000, 56:135-150. 10.1016/S0167-8140(00)00202-4, 10927132.
33. Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H. CT-based delineation of lymph node levels and related CTVs in the node negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003, 69:227-236. 10.1016/j.radonc.2003.09.011, 14644481.
34. Levendag P, Braaksma M, Coche E, van Der Est H, Hamoir M, Muller K, Noever I, Nowak P, van Sörensen De Koste J, Grégoire V. Rotterdam and Brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American academy of otolaryngology-head and neck surgery. Int J Radiat Oncol Biol Phys 2004, 58:113-123. 10.1016/S0360-3016(03)01453-6, 14697428.
35. Poon I, Fischbein N, Lee N, Akazawa P, Xia P, Quivey J, Phillips T. A population-based atlas and clinical target volume for the head-and-neck lymph nodes. Int J Radiat Oncol Biol Phys 2004, 59:1301-1311. 10.1016/j.ijrobp.2004.01.038, 15275713.
36. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA. Committee for Neck Dissection Classification, American Head and Neck Society. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 2008, 134:536-538. 10.1001/archotol.134.5.536, 18490577.